Tight junction in blood-brain barrier: An overview of structure, regulation, and regulator substances

CNS Neuroscience and Therapeutics

Volumn 18, Issue 8, 2012, Pages 609-615

  Liu, Wei Ye ^a   Wang, Zhi Bin ^a   Zhang, Li Chao ^b   Wei, Xin ^a   Li, Ling ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI SEVENTH PEOPLE S HOSPITAL   (China)

Author keywords

Blood brain barrier; Tight junctions; Vascular permeability

Indexed keywords

CLAUDIN 1; CLAUDIN 11; CLAUDIN 2; CLAUDIN 3; CLAUDIN 5; CYCLODEXTRIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JUNCTIONAL ADHESION MOLECULE A; MATRIX METALLOPROTEINASE; OCCLUDIN; PROTEIN ZO1; PROTEIN ZO2;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DIABETES MELLITUS; DRUG ABUSE; HORMONE DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOXIA; INFLAMMATION; ISCHEMIA; NONHUMAN; PATHOLOGY; REVIEW; STROKE; TIGHT JUNCTION;

ANIMALS; BLOOD-BRAIN BARRIER; CLAUDINS; CYTOPLASM; ENVIRONMENT; HORMONES; HUMANS; NEURAL CELL ADHESION MOLECULES; OCCLUDIN; TIGHT JUNCTION PROTEINS; TIGHT JUNCTIONS;

EID: 84864760434     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00340.x     Document Type: Review

References (105)

1. Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Res Rev 2010;64:328-363.
2. Tam SJ, Watts RJ. Connecting vascular and nervous system development: Angiogenesis and the blood-brain barrier. Annu Rev Neurosci 2010;33:379-408.
3. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57:173-185.
4. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12:54-61.
5. Neuwelt EA. Mechanisms of disease: The blood-brain barrier. Neurosurgery 2004;54:131-140; discussion 141-132.
6. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6:650-661.
7. Jeffrey P, Summerfield SG. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 2007;37:1135-1151.
8. Daneman R, Barres BA. The blood-brain barrier-lessons from moody flies. Cell 2005;123:9-12.
9. Petty MA, Lo EH. Junctional complexes of the blood-brain barrier: Permeability changes in neuroinflammation. Prog Neurobiol 2002;68:311-323.
10. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: A dynamic duo. Annu Rev Physiol 2011;73:283-309.
11. Feldman GJ, Mullin JM, Ryan MP. Occludin: Structure, function and regulation. Adv Drug Deliv Rev 2005;57:883-917.
12. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003;81:1-44.
13. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000;20:57-76.
14. Saitou M, Furuse M, Sasaki H, et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 2000;11:4131-4142.
15. Zlokovic B. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178-201.
16. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001;24:719-725.
17. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008;32:200-219.
18. Romanitan MO, Popescu BO, Spulber S, et al. Altered expression of claudin family proteins in Alzheimer's disease and vascular dementia brains. J Cell Mol Med 2010;14:1088-1100.
19. Ueno M. Molecular anatomy of the brain endothelial barrier: An overview of the distributional features. Curr Med Chem 2007;14:1199-1206.
20. Amasheh S, Milatz S, Krug SM, et al. Tight junction proteins as channel formers and barrier builders. Ann N Y Acad Sci 2009;1165:211-219.
21. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003;161:653-660.
22. Honda M, Nakagawa S, Hayashi K, et al. Adrenomedullin improves the blood-brain barrier function through the expression of claudin-5. Cell Mol Neurobiol 2006;26:109-118.
23. Zhang J, Piontek J, Wolburg H, et al. Establishment of a neuroepithelial barrier by Claudin5a is essential for zebrafish brain ventricular lumen expansion. Proc Natl Acad Sci U S A 2010;107:1425-1430.
24. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: An overview-structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1-13.
25. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007;7:467-477.
26. Bradfield PF, Nourshargh S, Aurrand-Lions M, Imhof BA. JAM family and related proteins in leukocyte migration (Vestweber series). Arterioscler Thromb Vasc Biol 2007;27:2104-2112.
27. Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev 2005;57:857-867.
28. Shin K, Margolis B. ZOning out tight junctions. Cell 2006;126:647-649.
29. Bauer H, Zweimueller-Mayer J, Steinbacher P, Lametschwandtner A, Bauer HC. The dual role of zonula occludens (ZO) proteins. J Biomed Biotechnol 2010;2010:402593.
30. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: Molecular organization and role in vascular homeostasis. Physiol Rev 2004;84:869-901.
31. Umeda K, Ikenouchi J, Katahira-Tayama S, et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006;126:741-754.
32. Umeda K, Matsui T, Nakayama M, et al. Establishment and characterization of cultured epithelial cells lacking expression of ZO-1. J Biol Chem 2004;279:44785-44794.
33. Xu J, Kausalya PJ, Phua DC, Ali SM, Hossain Z, Hunziker W. Early embryonic lethality of mice lacking ZO-2, but Not ZO-3, reveals critical and nonredundant roles for individual zonula occludens proteins in mammalian development. Mol Cell Biol 2008;28:1669-1678.
34. Inoko A, Itoh M, Tamura A, Matsuda M, Furuse M, Tsukita S. Expression and distribution of ZO 3, a tight junction MAGUK protein, in mouse tissues. Genes Cells 2003;8:837-845.
35. D'Atri F, Citi S. Cingulin interacts with F-actin in vitro. FEBS Lett 2001;507:21-24.
36. Guillemot L, Hammar E, Kaister C, et al. Disruption of the cingulin gene does not prevent tight junction formation but alters gene expression. J Cell Sci 2004;117:5245-5256.
37. Paschoud S, Citi S. Inducible overexpression of cingulin in stably transfected MDCK cells does not affect tight junction organization and gene expression. Mol Membr Biol 2008;25:1-13.
38. D'Atri F, Citi S. Molecular complexity of vertebrate tight junctions (Review). Mol Membr Biol 2002;19:103-112.
39. Satoh H, Zhong Y, Isomura H, et al. Localization of 7H6 tight junction-associated antigen along the cell border of vascular endothelial cells correlates with paracellular barrier function against ions, large molecules, and cancer cells. Exp Cell Res 1996;222:269-274.
40. Medeiros R, Baglietto-Vargas D, LaFerla FM. The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther 2011;17:514-524.
41. Caraci F, Battaglia G, Bruno V, et al. TGF-beta1 Pathway as a new target for neuroprotection in alzheimer's disease. CNS Neurosci Ther 2011;17:237-249.
42. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: Implications for drug therapy. Cell Transplant 2007;16:285-299.
43. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J. Blood-brain barrier permeability in Alzheimer's disease: A case-control MRI study. Psychiatry Res 2009;171:232-241.
44. Algotsson A, Winblad B. The integrity of the blood-brain barrier in Alzheimer's disease. Acta Neurol Scand 2007;115:403-408.
45. Guo JM, Liu AJ, Su DF. Genetics of stroke. Acta Pharmacol Sin 2010;31:1055-1064.
46. Yu JG, Zhou RR, Cai GJ. From hypertension to stroke: Mechanisms and potential prevention strategies. CNS Neurosci Ther 2011;17:577-584.
47. Liebeskind DS. Imaging the future of stroke: I. Ischemia. Ann Neurol 2009;66:574-590.
48. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 2008;112:3555-3562.
49. Koto T, Takubo K, Ishida S, et al. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 2007;170:1389-1397.
50. Willis CL, Meske DS, Davis TP. Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation. J Cereb Blood Flow Metab 2010;30:1847-1859.
51. Natah SS, Srinivasan S, Pittman Q, Zhao Z, Dunn JF. Effects of acute hypoxia and hyperthermia on the permeability of the blood-brain barrier in adult rats. J Appl Physiol 2009;107:1348-1356.
52. Yang Y, Rosenberg GA. MMP-mediated disruption of Claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol Biol 2011;762:333-345.
53. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007;27:697-709.
54. Liu W, Hendren J, Qin XJ, Shen J, Liu KJ. Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 2009;108:811-820.
55. Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol-Heart C 2005;289:H738-743.
56. McCaffrey G, Seelbach MJ, Staatz WD, et al. Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem 2008;106:2395-2409.
57. Nishioku T, Yamauchi A, Takata F, et al. Disruption of the blood-brain barrier in collagen-induced arthritic mice. Neurosci Lett 2010;482:208-211.
58. Nakajima A, Inoue E, Tanaka E, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 2010;39:360-367.
59. Sellner J, Weber MS, Vollmar P, Mattle HP, Hemmer B, Stuve O. The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: Enthusiasm lost too soon?CNS Neurosci Ther 2010;16:362-373.
60. Vos CM, Geurts JJ, Montagne L, et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 2005;20:953-960.
61. Kirk J, Plumb J, Mirakhur M, McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003;201:319-327.
62. Cheng Z, Zhang J, Liu H, Li Y, Zhao Y, Yang E. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption. Drug Metab Dispos 2010;38:1355-1361.
63. Horani MH, Mooradian AD. Effect of diabetes on the blood brain barrier. Curr Pharm Des 2003;9:833-840.
64. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl) 2004;82:510-529.
65. Huber JD. Diabetes, cognitive function, and the blood-brain barrier. Curr Pharm Des 2008;14:1594-1600.
66. Huber JD, VanGilder RL, Houser KA. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am J Physiol-Heart C 2006;291:H2660-H2668.
67. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007;50:202-211.
68. Sharma HS, Patnaik R, Sharma A. Diabetes aggravates nanoparticles induced breakdown of the blood-brain barrier permeability, brain edema formation, alterations in cerebral blood flow and neuronal injury. An experimental study using physiological and morphological investigations in the rat. J Nanosci Nanotechnol 2010;10:7931-7945.
69. Kanoski SE, Zhang Y, Zheng W, Davidson TL. The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat. J Alzheimers Dis 2010;21:207-219.
70. Toborek M, Lee YW, Flora G, et al. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005;25:181-199.
71. Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 2003;74:255-265.
72. Andras IE, Toborek M. HIV-1-induced alterations of Claudin-5 expression at the blood-brain barrier level. Methods Mol Biol 2011;762:355-370.
73. Huang W, Eum SY, Andras IE, Hennig B, Toborek M. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J 2009;23:1596-1606.
74. Persidsky Y, Heilman D, Haorah J, et al. Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 2006;107:4770-4780.
75. Andras IE, Pu H, Tian J, et al. Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 2005;25:1159-1170.
76. Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 2008;111:2062-2072.
77. Pu H, Hayashi K, Andras IE, Eum SY, Hennig B, Toborek M. Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. Brain Res 2007;1184:333-344.
78. Sharma HS, Kiyatkin EA. Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: An experimental study using light and electron microscopy. J Chem Neuroanat 2009;37:18-32.
79. Silva AP, Martins T, Baptista S, Goncalves J, Agasse F, Malva JO. Brain injury associated with widely abused amphetamines: Neuroinflammation, neurogenesis and blood-brain barrier. Curr Drug Abuse Rev 2010;3:239-254.
80. Martins T, Baptista S, Goncalves J, et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: Role of tight junction proteins and matrix metalloproteinase-9. Brain Res 2011;1411:28-40.
81. Ramirez SH, Potula R, Fan S, et al. Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 2009;29:1933-1945.
82. Yao H, Duan M, Buch S. Cocaine-mediated induction of platelet-derived growth factor: Implication for increased vascular permeability. Blood 2011;117:2538-2547.
83. Mahajan SD, Aalinkeel R, Sykes DE, et al. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 2008;1203:133-148.
84. Mahajan SD, Aalinkeel R, Sykes DE, et al. Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability. J Clin Immunol 2008;28:528-541.
85. Dhillon NK, Peng F, Bokhari S, et al. Cocaine-mediated alteration in tight junction protein expression and modulation of CCL2/CCR2 axis across the blood-brain barrier: Implications for HIV-dementia. J Neuroimmune Pharmacol 2008;3:52-56.
86. Dhillon NK, Gadgil M, Rahardja A, et al. Cocaine: A catalyst for human immunodeficiency virus-associated dementia. Am J Infectious Dis 2008;4:131-139.
87. Colgan OC, Ferguson G, Collins NT, et al. Regulation of bovine brain microvascular endothelial tight junction assembly and barrier function by laminar shear stress. Am J Physiol-Heart C 2007;292:H3190-H3197.
88. Helms HC, Waagepetersen HS, Nielsen CU, Brodin B. Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood-brain barrier model by increasing media buffer capacity during growth. AAPS J 2010;12:759-770.
89. Chen L, Yokel RA, Hennig B, Toborek M. Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature. J Neuroimmune Pharmacol 2008;3:286-295.
90. Jeliazkova-Mecheva VV, Hymer WC, Nicholas NC, Bobilya DJ. Brief heat shock affects the permeability and thermotolerance of an in vitro blood-brain barrier model of porcine brain microvascular endothelial cells. Microvasc Res 2006;71:108-114.
91. Sheikov N, McDannold N, Sharma S, Hynynen K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 2008;34:1093-1104.
92. Fan L, Liu Y, Ying H, et al. Increasing of blood-tumor barrier permeability through paracellular pathway by low-frequency ultrasound irradiation in vitro. J Mol Neurosci 2011;43:541-548.
93. Ding GR, Qiu LB, Wang XW, et al. EMP-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. Toxicol Lett 2010;196:154-160.
94. Stirone C, Duckles SP, Krause DN. Multiple forms of estrogen receptor-alpha in cerebral blood vessels: Regulation by estrogen. Am J Physiol Endocrinol Metab 2003;284:E184-192.
95. Bake S, Sohrabji F. 17beta-estradiol differentially regulates blood-brain barrier permeability in young and aging female rats. Endocrinol 2004;145:5471-5475.
96. Bake S, Friedman JA, Sohrabji F. Reproductive age-related changes in the blood brain barrier: Expression of IgG and tight junction proteins. Microvasc Res 2009;78:413-424.
97. Sandoval KE, Witt KA. Age and 17beta-estradiol effects on blood-brain barrier tight junction and estrogen receptor proteins in ovariectomized rats. Microvasc Res 2011;81:198-205.
98. Forster C, Silwedel C, Golenhofen N, et al. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol 2005;565:475-486.
99. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 2008;586:1937-1949.
100. Sadowska GB, Malaeb SN, Stonestreet BS. Maternal glucocorticoid exposure alters tight junction protein expression in the brain of fetal sheep. Am J Physiol Heart Circ Physiol 2010;298:H179-H188.
101. Lu R, Wang W, Uzzau S, Vigorito R, Zielke HR, Fasano A. Affinity purification and partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human brain. J Neurochem 2000;74:320-326.
102. Salama NN, Fasano A, Thakar M, Eddington ND. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents. J Pharmacol Exp Ther 2005;312:199-205.
103. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 2006;58:15-28.
104. Menon D, Karyekar CS, Fasano A, Lu R, Eddington ND. Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT. Int J Pharm 2005;306:122-131.
105. Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 2009;1788:892-910.